Summary & Overview
HCPCS Q5113: Trastuzumab-pkrb (Herzuma) 10 mg Injection
HCPCS Level II code Q5113 denotes a 10 mg vial of trastuzumab-pkrb, a biosimilar to trastuzumab marketed as Herzuma, used in HER2-targeted oncology treatment. This code identifies the specific biologic product administered and matters nationally because biosimilar uptake influences drug spending, formulary decisions, and provider billing workflows for cancer therapies. Clear coding supports accurate claims processing and tracking of biosimilar utilization.
Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find national context on clinical use and coding relevance, payer coverage considerations, and where to look for benchmarking and policy updates. The publication outlines how this HCPCS Level II code fits into oncology drug administration workflows and the implications for claim adjudication and reporting.
The report summarizes benchmarks and payer coverage trends where available, highlights relevant policy updates affecting biosimilar reimbursement and coding, and provides clinical context for trastuzumab biosimilar use in HER2-positive cancers. Data not available in the input will be noted as such and omitted from sections requiring specific values.
Billing Code Overview
HCPCS Level II code Q5113 represents an injection of trastuzumab-pkrb, a biosimilar marketed as Herzuma, in a 10 mg vial. The code denotes the specific biologic agent used for HER2-directed therapy.
Service type: Therapeutic monoclonal antibody administration (oncology biologic)
Typical site of service: Outpatient infusion center or hospital outpatient department
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with HER2-positive breast cancer receiving an intravenous oncology biologic. The procedure is administration of the trastuzumab biosimilar Q5113 (trastuzumab-pkrb, Herzuma) billed per 10 mg vial. The patient presents to an outpatient oncology infusion center or hospital outpatient infusion clinic for scheduled dosing every 1–3 weeks depending on regimen. Pre-infusion workflow includes verification of diagnosis and orders, weight-based dose calculation, review of prior reaction history, baseline vital signs, and confirmation of required cardiac monitoring (e.g., recent echocardiogram or MUGA). Pharmacy prepares the appropriate number of Q5113 vials, labels for sterile compounding, and documents lot numbers for traceability. Nursing obtains IV access, confirms consents, and administers pre-medications if indicated. The infusion is delivered per institutional protocol with monitoring for infusion reactions and cardiotoxicity. Post-infusion documentation includes administered drug name and dose (Q5113 quantity), lot/expiration, start and stop times, patient tolerance, and any adverse events. Typical sites of service are outpatient hospital infusion centers, physician office infusion suites, and ambulatory infusion clinics. Common payer interactions include prior authorization for trastuzumab biosimilars, medical necessity documentation citing HER2-positive malignancy, and coding the J/HQ/Q HCPCS appropriately with applicable modifiers for circumstances such as inpatient/outpatient status, drug wastage, or discarded drug. The clinical scenario often involves coordination among medical oncology, pharmacy, infusion nursing, and billing teams to ensure accurate documentation and reimbursement for Q5113 administrations.